User login
Key clinical point: Combination therapy of methotrexate with tofacitinib or adalimumab improved outcomes in patients with rheumatoid arthritis (RA) who did not respond well to tofacitinib alone.
Major finding: Overall, greater response was achieved by 28.8%, 37.2%, and 39.1% of patients receiving tofacitinib monotherapy, tofacitinib + metotrexate, and adalimumab + methotrexate, respectively. Patients with greater response showed similar 12-month cumulative probability plots for a mean percentage change in Clinical Disease Activity Index across treatment. However, patients with lower responses receiving tofacitinib monotherapy did not respond as well as those receiving combination therapies.
Study details: The data come from a post hoc analysis of the ORAL Strategy trial, which included 1,146 patients with active RA despite methotrexate treatment who were randomly assigned to receive 5 mg tofacitinib twice daily, 5 mg tofacitinib twice daily + methotrexate, or 40 mg adalimumab every other week + methotrexate.
Disclosures: This study was funded by Pfizer Inc. Some of the authors reported receiving grants/research support and consultancy fees from various sources including Pfizer Inc. J Paulissen reported being an employee of Syneos Health. N Iikuni, H Shi, K Soma, and T Hirose reported being employees and shareholders of Pfizer Inc.
Source: Takeuchi T et al. Arthritis Res Ther. 2021 Aug 24. doi: 10.1186/s13075-021-02591-y.
Key clinical point: Combination therapy of methotrexate with tofacitinib or adalimumab improved outcomes in patients with rheumatoid arthritis (RA) who did not respond well to tofacitinib alone.
Major finding: Overall, greater response was achieved by 28.8%, 37.2%, and 39.1% of patients receiving tofacitinib monotherapy, tofacitinib + metotrexate, and adalimumab + methotrexate, respectively. Patients with greater response showed similar 12-month cumulative probability plots for a mean percentage change in Clinical Disease Activity Index across treatment. However, patients with lower responses receiving tofacitinib monotherapy did not respond as well as those receiving combination therapies.
Study details: The data come from a post hoc analysis of the ORAL Strategy trial, which included 1,146 patients with active RA despite methotrexate treatment who were randomly assigned to receive 5 mg tofacitinib twice daily, 5 mg tofacitinib twice daily + methotrexate, or 40 mg adalimumab every other week + methotrexate.
Disclosures: This study was funded by Pfizer Inc. Some of the authors reported receiving grants/research support and consultancy fees from various sources including Pfizer Inc. J Paulissen reported being an employee of Syneos Health. N Iikuni, H Shi, K Soma, and T Hirose reported being employees and shareholders of Pfizer Inc.
Source: Takeuchi T et al. Arthritis Res Ther. 2021 Aug 24. doi: 10.1186/s13075-021-02591-y.
Key clinical point: Combination therapy of methotrexate with tofacitinib or adalimumab improved outcomes in patients with rheumatoid arthritis (RA) who did not respond well to tofacitinib alone.
Major finding: Overall, greater response was achieved by 28.8%, 37.2%, and 39.1% of patients receiving tofacitinib monotherapy, tofacitinib + metotrexate, and adalimumab + methotrexate, respectively. Patients with greater response showed similar 12-month cumulative probability plots for a mean percentage change in Clinical Disease Activity Index across treatment. However, patients with lower responses receiving tofacitinib monotherapy did not respond as well as those receiving combination therapies.
Study details: The data come from a post hoc analysis of the ORAL Strategy trial, which included 1,146 patients with active RA despite methotrexate treatment who were randomly assigned to receive 5 mg tofacitinib twice daily, 5 mg tofacitinib twice daily + methotrexate, or 40 mg adalimumab every other week + methotrexate.
Disclosures: This study was funded by Pfizer Inc. Some of the authors reported receiving grants/research support and consultancy fees from various sources including Pfizer Inc. J Paulissen reported being an employee of Syneos Health. N Iikuni, H Shi, K Soma, and T Hirose reported being employees and shareholders of Pfizer Inc.
Source: Takeuchi T et al. Arthritis Res Ther. 2021 Aug 24. doi: 10.1186/s13075-021-02591-y.